Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
Viant (DSP): AI-First DSP — A Tactical Long on Automation Driving Margin Rebound
Programmatic ad trading gone autonomous. Improving unit economics and sequential revenue momentum make DSP a tactical buy despite a messy ownership footprint.
Viant’s DSP business is showing sequential revenue and gross-profit improvement alongside a return to operating profitability in Q3 2025. The compan...
Bruker (BRKR) - Putting a Floor Under the Stock Ahead of an Earnings Pivot
Q3 disappointment creates a tactical long opportunity — attractive entry, defined risk and clear catalysts.
Bruker reported a rough Q3 with an operating loss driven by one-time items and higher operating expenses, but the underlying business (portable instru...
Buy Time Extended: Exxon Mobil (XOM) — Income, Cash Flow and a Tactical Entry
High cash generation, rising dividend, and a solid balance sheet make XOM a pragmatic buy through volatile oil cycles — entry, stops, and targets included.
Exxon Mobil (XOM) remains a constructive trade in early 2026. Strong operating cash flow, a healthy balance sheet, and a newly elevated quarterly divi...
Adding to Booz Allen (BAH): Modest Overweight for a Cash-Generative, Defense-Tech Compounder
Defense/A&I exposure, reliable cash flow and a still-reasonable multiple — buying into a near-term overshoot and a multi-quarter recovery.
Booz Allen Hamilton is a government-focused tech and consulting franchise with strong operating cash flow, an attractive ~2.3% dividend yield, and a b...
AQST: Tactical Long Into the Anaphylm PDUFA - Small Position, Big Binary Upside
Buy a limited-sized position ahead of the FDA decision; use tight risk management and two-tier targets for approval vs. safe-harbor outcomes.
Aquestive (AQST) is a small commercial-stage specialty pharma with a binary near-term catalyst: the potential FDA decision on Anaphylm (epinephrine su...
Why Zevia Could Be a High-ROI CPG Growth Trade - A Risk-Managed Long
Brand pricing power, healthier balance sheet, improving cash flow — buy the turnaround with a tight stop.
Zevia (ZVIA) looks like a classic small-cap CPG rebound: strong gross margins (45-50%), improving operating cash flow, shrinking inventory and a clean...
Ferrari at a Crossroads: Premium Price, Durable Franchise - A Tactical Long
Buy the brand, not the macro - an actionable long with defined entry, stops and targets.
Ferrari trades at a premium but retains pricing power, controlled supply and supportive capital returns. Recent buyback activity, a rising dividend an...
Elanco Animal Health: Innovation-Fueled Upside With Visible Deleveraging — Tactical Long
Pipeline momentum plus consistent cash generation has pulled leverage down; we like a tactical long with explicit stops and two-stage targets.
Elanco (ELAN) is showing the two things investors want to see after years of integration and restructuring: improving free cash generation and a falli...
From Optionality To Certainty: Why Omega Healthcare Is the Better High-Yield REIT Trade Right Now
OHI's cash-flow consistency, coverage, and balance-sheet posture make it a cleaner income trade versus riskier healthcare REIT peers.
Omega Healthcare Investors (OHI) offers yield with stability: steady quarterly dividends ($0.67/qtr), consistent operating cash flow (three most recen...
DuPont Re-Rating: Buy the Specialist as Earnings Quality and Cash Flow Take Center Stage
Specialty focus, cleaner operations and strong cash flow argue for a re-rating — enter the position around $43, stop tight, targets above $55.
DuPont's transformation into a leaner specialty-chemicals operator is entering the phase where the market can reward higher multiples. Continuing oper...
Tenax Therapeutics: Speculative Buy on Clinical Optionality and Clean Balance Sheet
Levosimendan rights and Phase 2 data give upside; buy on weakness with tight size and stop-loss.
Tenax (TENX) is a small-cap specialty pharma holding North American rights to levosimendan. The stock has roughly doubled in the past year to $13.12 (...
Life Time Group (LTH): Profitable Growth and Deleveraging Create a Favored Long Setup
A data-driven trade idea: constructive on membership-driven revenue growth, cash conversion and falling debt.
Life Time (LTH) shows accelerating revenue and profit, strong operating cash flow and clear deleveraging. The shares trade at a reasonable multiple ve...